Jetbio has been established to commercialise Newcastle University's patented (WO2019008373) bioprinting technology. Our reactive jet impingement (ReJI) bioprinting technology is a fast, flexible system for printing biomimetic cell filled gels for use in developing in vitro disease models for drug testing, or to support regenerative medicine.

The research and development which led to the  ReJI bioprinting process has been led by Professor Kenny Dalgarno and supported by the EPSRC, the EC, Versus Arthritis, and the MRC. Key publications are:

• Ribeiro, R; Pal, D; Ferreira-Duarte, A; Gentile, P; Benning, M; Dalgarno, K. "Reactive jet impingement bioprinting of high cell density gels for bone microtissue fabrication." Biofabrication, 2018, doi: 10.1088/1758-5090/aaf625.
• Kotlarz M; Ferreira AM; Gentile P & Dalgarno K. Bioprinting of cell-laden hydrogels onto titanium alloy surfaces to produce a bioactive interface. Macromolecular Bioscience, 2022. doi: 10.1002/mabi.202200071.
• Kotlarz M, Ferreira AM, Gentile P, Russell SJ, Dalgarno K. Droplet-based bioprinting enables the fabrication of cell-hydrogel-microfibre composite tissue precursors. Bio-Design and Manufacture, 2022. doi: 10.1007/s42242-022-00192-5.
• Kotlarz M; Melo P; Ferreira AM; Gentile P & Dalgarno K. Cell seeding via bioprinted hydrogels supports cell migration into porous apatite-wollastonite bioceramic scaffolds for bone tissue engineering. Biomaterials Advances, 2023, doi: 10.1016/j.bioadv.2023.213532.

Currently securing seed round investment ahead of full commercial launch.

For further information contact Jetbio CEO Dennis Camilleri: dennis@jet-bio.com